|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030193,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0036525,
umls-concept:C0153690,
umls-concept:C0205088,
umls-concept:C0205369,
umls-concept:C0217843,
umls-concept:C0231220,
umls-concept:C0231491,
umls-concept:C0282460,
umls-concept:C0376358,
umls-concept:C0547040,
umls-concept:C0908489,
umls-concept:C0936012,
umls-concept:C1328193,
umls-concept:C1522484,
umls-concept:C2713006
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-9-15
|
|
pubmed:abstractText |
To report the final analysis of a Phase II trial, which investigated the safety and efficacy of the specific endothelin A receptor antagonist zibotentan (AstraZeneca, Macclesfield, UK) in patients with metastatic castration-resistant prostate cancer (CRPC).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1464-410X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2010 DRUG SAFETY RESEARCH UNIT.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
966-73
|
|
pubmed:dateRevised |
2011-2-1
|
|
pubmed:meshHeading |
pubmed-meshheading:20840318-Antineoplastic Agents,
pubmed-meshheading:20840318-Bone Neoplasms,
pubmed-meshheading:20840318-Epidemiologic Methods,
pubmed-meshheading:20840318-Follow-Up Studies,
pubmed-meshheading:20840318-Humans,
pubmed-meshheading:20840318-Male,
pubmed-meshheading:20840318-Neoplasms, Hormone-Dependent,
pubmed-meshheading:20840318-Orchiectomy,
pubmed-meshheading:20840318-Pain,
pubmed-meshheading:20840318-Prostatic Neoplasms,
pubmed-meshheading:20840318-Pyrrolidines,
pubmed-meshheading:20840318-Receptor, Endothelin A,
pubmed-meshheading:20840318-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
|
|
pubmed:affiliation |
Division of Cancer Studies, University of Birmingham, Birmingham, UK. n.d.james@bham.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
